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Elevation of intracellular cAMP concentration has numerous vascular protective effects that are in part mediated
via actin cytoskeleton-remodelling and subsequent regulation of gene expression. However, themechanisms are
incompletely understood. Here we investigated whether cAMP-induced actin-cytoskeleton remodelling modu-
lates VSMC behaviour by inhibiting expression of CCN1. In cultured rat VSMC, CCN1-silencing signiﬁcantly
inhibited BrdU incorporation andmigration in a wound healing assay. Recombinant CCN1 enhanced chemotaxis
in a Boyden chamber. Adding db-cAMP, or elevating cAMP using forskolin, signiﬁcantly inhibited CCN1 mRNA
and protein expression in vitro; transcriptional regulation was demonstrated by measuring pre-spliced CCN1
mRNA and CCN1-promoter activity. Forskolin also inhibited CCN1 expression in balloon injured rat carotid arter-
ies in vivo. Inhibiting RhoA activity, which regulates actin-polymerisation, by cAMP-elevation or pharmacologi-
cally with C3-transferase, or inhibiting its downstream kinase, ROCK, with Y27632, signiﬁcantly inhibited
CCN1 expression. Conversely, expression of constitutively active RhoA reversed the inhibitory effects of forskolin
onCCN1mRNA. Furthermore, CCN1mRNA levelswere signiﬁcantly decreased by inhibiting actin-polymerisation
with latrunculin B or increased by stimulating actin-polymerisation with Jasplakinolide. We next tested the role
of the actin-dependent SRF co-factor, MKL1, in CCN1 expression. Forskolin inhibited nuclear translocation of
MKL1 and binding of MKL1 to the CCN1 promoter. Constitutively-activeMKL1 enhanced basal promoter activity
ofwild-type but not SRE-mutated CCN1; and prevented forskolin inhibition. Furthermore, pharmacologicalMKL-
inhibitionwith CCG-1423 signiﬁcantly inhibited CCN1promoter activity aswell asmRNA and protein expression.
Our data demonstrates that cAMP-induced actin-cytoskeleton remodelling regulates expression of CCN1 through
MKL1: it highlights a novel cAMP-dependent mechanism controlling VSMC behaviour.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).
1. Introduction
3′-5′ cyclic adenosine monophosphate (cAMP) is a ubiquitous
second messenger synthesised in cells by several adenylyl cyclase iso-
enzymes in response to vasoactive Gs protein-coupled receptor stimula-
tion. cAMP regulates numerous, physiological, cellular functions that
are essential for normal blood vessel homeostasis, including prolifera-
tion[1], apoptosis[2], differentiation [3], relaxation[4] and inﬂamma-
tion[5]. In vascular smooth muscle cells (VSMC), elevated cAMP levels
inhibit mitogen stimulated proliferation in vitro [1] and injury induced
proliferation in vivo [6]. A number of studies have also demonstrated in-
hibitory effects of cAMP on VSMC migration [7,8], which together with
the aforementioned anti-mitogenic properties, reduce intimal lesion
formation in experimental vascular injurymodels [6,9]. Altered or aber-
rant cAMP signalling has also been implicated in development of many
vascular pathologies [10,11], including late vein-graft failure [12–14],
angioplasty restenosis [15], atherogenesis [16] and pulmonary hyper-
tension. For example, the ability of VSMC to synthesise cAMP is reduced
in response to hypertension [17], vein grafting [14], hypoxia and oxLDL
[18], suggesting that deregulation of cAMP signalling contributes to-
wards the development of vascular pathologies.
Activation of the cAMP sensitive protein kinase A (PKA) and
subsequent phosphorylation of CREB-dependent gene expression is
one well-established mechanism underlying cAMP-dependent cellular
responses [19]. However, recent evidence from our laboratory and
others implicates actin-cytoskeleton remodelling as an additional key
component of cAMP signalling in VSMC [20–23]. Elevated cAMP inhibits
the activity of members of the Rho GTPases, which in VSMC [20,23]
causes reduced actin polymerisation and acquisition of a ‘stellate’
like morphology, characterised by a loss of actin stress ﬁbres and a
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condensed cytoplasm. RhoA or Rac1 inhibition using pharmacological
inhibitors, siRNA or dominant-negative approaches mimics the effects
of cAMP on VSMC morphology, proliferation, migration and relaxation
in vitro and in vivo [20,23], demonstrating the functional role of Rho
GTPase inhibition for cAMP responses. Moreover, expression of
constitutively-active RhoA or Rac1 mutants effectively prevents cAMP-
induced actin cytoskeleton remodelling and reverses many of the
biological effects of cAMP in VSMC [20,22,23]. Although inhibition of
Rho GTPases and actin polymerisation is an important mechanism
underlying cAMP-dependent biological responses in VSMC, the
downstream pathways are unclear.
Actin-cytoskeleton remodelling controls expression of multiple genes
but it is not clear which, if any, contribute to the effects of cAMP in VSMC.
For example, formation of F-actin stress ﬁbres is required in many cell
types for efﬁcient mitogen-activated nuclear translocation of ERK1/2 ki-
nases and subsequent early response gene expression [24,25]. In addition,
increased levels of actin monomer (G-actin), resulting from impaired
actin polymerisation, has also been implicated in modulation of SRF-
dependent gene expression, via cytoplasmic sequestration of the SRF
co-factors such as MKL1 [26]. Regulation of transcription factor activity
via these actin-dependent mechanisms typically controls cell behaviour
by rapidly modulating expression of immediate early genes.
To identify genes that are regulated in response to cAMP-mediated
repression of RhoA signalling, we cross-referenced our previous
cAMP-dependent transcriptomic data [22] with the National Cancer
Institute’s pathway interaction database. This identiﬁed the Cysteine-
rich protein 61 (CCN1) gene as a putative cAMP and RhoA pathway-
dependent gene. CCN1 is a ~40 kDa secreted protein and member of
the CCN family of immediate-response genes that is rapidly induced
bymitogens, stress and tissue injury [27]. Importantly, CCN1 expression
in various tissues is regulated throughmechano-transduction pathways
that appear to converge at the level of cytoskeletal actin dynamics [28].
On synthesis, CCN1 is secreted and associates with the ECM or cell
surface to modulate a range cell functions, including adhesion, prolifer-
ation, migration, inﬂammation, ECM-remodelling and gene expres-
sion [29]. CCN1 is expressed in the vasculature during development
where it is essential for vascular integrity [30] and is up regulated in
adults in response to vessel injury and in advanced atherosclerotic
plaques where it contributes towards monocyte adhesion and intimal
lesion formation [31,32]. Here we ﬁrst inquired whether CCN1 regulat-
ed VSMC proliferation andmigration.We then investigated the hypoth-
esis that at cAMP elevation might repress expression of CCN1 in VSMC
by inhibiting RhoA-mediated actin polymerisation and reduced MKL1-
dependent transcription.
2. Material and methods
2.1. Materials
Male Sprague–Dawley (SD) rats were obtained from Charles River.
Culture media and additives were obtained from Invitrogen. All
chemicals were obtained from Sigma unless otherwise stated.
BAY606583 was from Tocris. Antibodies used were anti-CCN1 (R&D
Systems, #AF4055), anti-GAPDH (Millipore, #MAB374), anti-MKL1
(Santa Cruz #sc21558), anti-BrdU (Sigma; #B253).
2.2. Smooth muscle cell culture
Male Sprague–Dawley rats were killed by cervical dislocation in ac-
cordance with the Directive 2010/63/EU of the European Parliament.
Approval was granted by the University of Bristol ethical review
board. Medial tissue was carefully dissected from the thoracic aorta
and cut into 1 mm2 pieces for explant culture, essentially as described
previously [33]. Stimulations were performed in 5% foetal calf serum/
DMEM unless otherwise stated. Proliferation was measured by culture
in the presence of 10 μM bromo-deoxyuridine. Following ﬁxation in
70% ethanol, incorporated bromo-deoxyuridine was detected by
immuno-histochemical staining as previously described [21].
2.3. Balloon injury of rat carotid arteries and local administration
of forskolin
Male Sprague–Dawley rats were obtained from Charles River (UK).
The housing and care of the animals and all the procedures used in
the study adhered to the guidelines and regulations of Animal Scientiﬁc
Procedures Act 1986. Balloon injury of left common carotid artery was
performed as previously described [34]. Brieﬂy, rats were anesthetised
with ketamine (100mg/kg) and xylazine (5mg/kg; i.p.) following inha-
lation of halothane. Left common carotid arteries were injured by three
rotating passes with a 2F Forgaty catheter (Actamed, West Yorkshire,
UK) introduced through the left external carotid artery. Proximal exter-
nal carotid arteries were ligated after withdrawal of the balloon cathe-
ter. Where indicated, 200 μl of 30% (wt/vol) pluronic gel (F127,
Sigma) containing either forskolin (200 μmol/L) or 0.1%DMSO (control)
was applied around the injured common carotid arteries (~1 cm in
length) before closure of the wound. Rats were killed after 7 days
using pentobarbital (100 mg/kg i.p.) and vessels collected after perfu-
sion with heparinised PBS or perfusion-ﬁxation with 10% formalin/PBS
solution.
2.4. Immunohistochemistry
Formalin-ﬁxed, parafﬁn-embedded arterial sections were
deparafﬁnised, rehydrated and subjected to antigen retrieval (sodium
citrate buffer, 0.1 mol/L, pH = 6.0, at 100 °C for 10 min). Sections
were blocked with Image-iT FX (Life Technologies) and incubated
with 10 μg/ml sheep anti-CCN1 (R&D Systems, #AF4055), biotin-
conjugated secondary antibody (Dako), followed by detection with
Strepavidin Alexa-Fluor 488.
2.5. Migration and chemotaxis assays
VSMC migration was measured using Ibidi culture-inserts with a
500 μm gap width. Inserts were attached to the bottom of 24 well
plate wells. Cells were transfected with the indicated siRNAs (as de-
scribed in Section 2.8) and seeded into both chambers of the Ibidi insert.
After 24 h, inserts were removed and cells were allowed tomigrate into
the exposed wound area for a further 18 h. Cell numbers migrating into
the wound area were counted. Chemotaxis assays were performed
using a 48 well Neuro Probe chemotaxis chamber ﬁtted with a polycar-
bonate membrane (8 μm pore size). The lower chamber was ﬁlled with
serum free media containing the indicated amounts of recombinant
CCN1. Serumdeprived cells were trypsinised, seeded into the top cham-
ber in serum free medium and allowed to migrate for 6 h. Cells on the
top of the membrane were removed with gentle abrasion and the
lower side stained with hemotoxylin. Migrated cells were counted and
expressed as migrated cells per high power ﬁeld.
2.6. Quantitative RT-PCR and Western blotting
Quantiﬁcation of mRNA and protein levels was performed by qRT-
PCR and Western blotting essentially as described previously [21].
Total RNA, extracted using Qiagen RNeasy kit (Qiagen) was reverse
transcribed using QuantiTect RT kit (Qiagen) and random primers.
Quantitative PCR was performed using Roche SYBR Green using an
Illumina Eco PCR machine (20′@95 °C; 20′@62 °C; 20′@72 °C). Data
were normalised to total RNA levels in each reaction. Primers were:
rat CCN1 forward 5′-GGA ACT GGC ATC TCC ACA CGA GTT-3′ and re-
verse 5′-TTG TCC ACA AGG ACG CAC TTC ACA-3′; rat CCN1 pre-spliced
hnRNA forward 5′-CAG CTC ACT GAA GAG GCT TCC TGG-3′ and reverse
5′-TAG ACC GGTGCAGAC ACACAA TGG-3′; rat 36B4mRNA forward 5′-
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AGC CAA GGT CGA AGC AAA GGA AGA-3′ and reverse 5′-GAC TTG GTG
TGA GGG GCT TAG TCG-3′.
2.7. Plasmids, siRNA and adenoviral vectors
A 2.177 kb fragment of the human CCN1 promoter (Hg19;
chr1:86044316-chr1:86046493) was ampliﬁed from human genomic
DNA and cloned into the Kpn1 and Nhe1 restriction sites of pGL4
[luc2CP] (Promega). pSRE-Luc luciferase reporter containing ﬁve copies
of an SRE element was obtained from Agilent. p3XCMVFLAG-wt-MKL
and p3XCMVFLAG-MKL1N100 vectors expressing wild-type and
constitutively-active MKL1 that lacks the N-terminal 100 amino acid
actin-binding domain were a gift from Prof. Ron Prywes and have
been described previously [35]. An EcoR1 and BamH1 fragment cut
from p3XCMVFLAG-MKL1N100 was sub-cloned into pDC515 (Microbix)
and used to generate the recombinant adenovirus expressingMKL1N100.
Recombinant adenovirus expressing constitutively active RhoA(G14V)
has been described previously [22]. Silencer Select siRNAs targeting
rat CCN1 (s135923 and s135925), rat MKL1 (s163756) and rat MKL2
(ABX00O2) were purchased from Life Technolgies. Recombinant CCN1
protein was obtained from Peprotech. Pharmacological MKL inhibitor
CCG-1423 was obtained from Cayman Chemical. pCS2+/hSRF-VP16
plasmid was provided by Alfred Nordheim [36].
2.8. Transfection and recombinant adenoviruses transduction
Plasmid transfection was performed using nucleofection. 1 × 106
VSMC were transfected with 3–5 μg of DNA using program A033.
Adenoviruses were prepared as previously described [20]. VSMC were
infected with adenovirus at 1 × 108 plaque forming units/ml for 16 h.
2.9. Reporter gene luciferase assays
Cells were transfected by electroporationwith the indicated SRE and
CCN1 promoter reporter plasmids together with pTk-Renilla for
normalisation. Cells were stimulated with the indicated agents 24 h
post-transfection followed by lysis in Promega cell culture lysis buffer.
Luciferase and Renilla activity were quantiﬁed using the dual reporter
assay kit (Promega) according to the manufacturer's instructions
using Glomax luminometer (Promega).
2.10. Chromatin immunoprecipitation (ChIP) assays
ChIP assayswere performed essentially as described previously [37].
ChIP primers used to amplify an amplicon located near the rat CCN1
promoter SRE element were 5′-AAC GCA GGC TAC TGC TAT ACC CAA
A-3′ and reverse 5′-CCT GGC TTC TGT TGT GGC GTC TTT T-3′.
2.11. Statistical analysis
Statistical analysiswas performed using ANOVAwith Student–New-
man–Keuls post-test or where appropriate a paired Student's t-test. All
data are fromat least three independent experiments and are presented
as mean ± standard error. * indicates p b 0.05, ** indicates p b 0.01, ***
indicates p b 0.001.
3. Results
3.1. CCN1 regulates VSMC proliferation, migration and chemotaxis
Elevation of intracellular cAMP inhibits proliferation and migration
of several cell types, including VSMC [38–40]. Based on this, we
hypothesised that cAMP-mediated repression of CCN1might contribute
towards reduced VSMC proliferation and migration. We therefore test-
ed the effects of siRNA-mediated silencing of CCN1 and recombinant
CCN1 protein on VSMC proliferation and migration. Transfection with
siRNA targeting CCN1 (siCCN1) but not a control siRNA (siNEG) reduced
CCN1 protein levels to below the limit of detection without effecting
GAPDH protein levels (Fig. 1A). SiCCN1 signiﬁcantly inhibited prolifera-
tion measured by BrdU incorporation to 48.2 ± 2.9% of controls
(Fig. 1B). PDGFBB stimulation dose-dependently increased VSMC
migration of siNEG transfected cells in in vitro wound healing assays
(Fig. 1C). CCN1 silencing signiﬁcantly reduced migration into the
wound area induced by 10 ng/ml PDGFBB from 274.9 ± 43.1 cells/
wound area to 126.5 ± 22.23 cell/wound area (p b 0.0216; Fig. 1C and
D). Furthermore, Boyden chamber chemotaxis assays demonstrated
that recombinant CCN1 protein dose dependently stimulated VSMC
chemotaxis (Fig. 1E and F).
Fig. 1. CCN1 promotes VSMC proliferation, migration and chemotaxis. Western blot
analysis of CCN1 and GAPDH protein 24 h post-transfection with siNEG (□) or siCCN1( )
(A). Relative BrDU incorporation 24–40 h post-transfection with siNEG of siCCN1; n = 3
(B). Barrier migration assay of siNEG (□) and siCCN1( ) transfected cells after 18 h
stimulation with 2.5 ng/ml or 10 ng/ml PDGFBB; n = 6 (C and D). Boyden-chamber
chemotaxis assay using 5 or 20 μg/ml recombinant CCN1 in the bottom chamber
for 8 h; n = 6 (E and F). □ indicates controls; indicates stimulated cells. * indicates p b
0.05; ** indicates p b 0.01; *** indicates p b 0.001.
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3.2. Elevated cAMP inhibits mitogen-induced expression of CCN1 in vitro
and injury-induced expression of CCN1 in vivo
To begin understanding the regulation of CCN1 by cAMP in VSMC,
we used the stable cAMP analogue dibutyryl-cAMP (db-cAMP) and
the adenylate cyclase activator forskolin. Stimulation with db-cAMP
for 2 h signiﬁcantly and concentration-dependently inhibited CCN1
mRNA levels without effecting mRNA levels of the housekeeping gene,
36B4 (Fig. 2A). Stimulation with 500 μM db-cAMP demonstrated a
rapid (by 2 h) and sustained (up to 16 h), signiﬁcant inhibition of
CCN1 mRNA levels (Fig. 2B), while 36B4 mRNA levels remained
unaffected. We next used forskolin, to test the role of endogenously
produced cAMP. Forskolin stimulation resulted in a transient but signif-
icant stimulation of CCN1mRNA levels at 1 h but a dramatic and highly
Fig. 2. cAMP inhibits expression of CCN1 in VSMC. VSMCswere stimulatedwith for 2 hwith the indicated concentrations of db-cAMP; n=3 (A), with 500 μMdb-cAMP for the indicated
times; n= 3 (B) or with 25 μM forskolin for the indicated times; n= 3 (C). Quiescent VSMCs were stimulatedwith 50 ng/ml PDGFBB for 1 h with 25 μM forskolin as indicated; n= 6 (D).
Total RNAwas analysed for CCN1 (dashed line) and 36B4mRNA (solid line) using RT-PCR (A–D). Cellswere stimulatedwith 25 μMforskolin (E) or 500 μMdb-cAMP (F) for indicated times
and CCN1 protein quantiﬁed byWestern blotting and densitometry at 8 h; n = 3;□ indicates control; indicates stimulated (G). Quiescent VSMCs were stimulated with 10% FCS (H) or
50 ng/ml PDGFBB (I) for indicated times and CCN1 protein quantiﬁed by Western blotting. (J) Quiescent VSMCs were stimulated with 10% FCS (H) or 50 ng/ml PDGFBB for 1 h in the
presence of 25 μM forskolin or 500 μM db-cAMP, as indicated. CCN1 protein was quantiﬁed by Western blotting. * indicates p b 0.05, ** indicates p b 0.01, *** indicates p b 0.001.
160 A. Duggirala et al. / Journal of Molecular and Cellular Cardiology 79 (2015) 157–168
signiﬁcant inhibition after 2 h (to 2.6 ± 1.05% of controls) and 4 h (to
2.4 ± 6.6% of controls) (Fig. 2C). Furthermore, forskolin completely re-
versed the increase in CCN1mRNA induced by PDGFBB (Fig. 2D). Impor-
tantly, db-cAMP and forskolin also reduced CCN1 protein levels as early
as 2 h after stimulation (Fig. 2E and F). The inhibition by db-cAMP (to
44.7 ± 6.9% of control; p b 0.01) and forskolin (to 27.3 ± 5.2% of con-
trols; p b 0.01) was signiﬁcant after 8 h (Fig. 2G). Stimulation of quies-
cent cells with 10% serum mitogens resulted in a rapid (3.5 ± 0.3 fold;
p b 0.001 after 1 h) and sustained (up to 8 h) increase in CCN1 protein
levels (Fig. 2H and J). Stimulation with PDGFBB resulted in a weaker
but still signiﬁcant (2 ± 0.22 fold at 1 h; p b 0.01) and transient up-
regulation of CCN1 protein (Fig. 2I and J). Importantly, db-cAMP and
forskolin both completely reverse the increase in CCN1protein levels in-
duced by either 10% serum or PDGFBB (Fig. 2J). A similar forskolin-
mediated inhibition of CCN1 mRNA and protein was detected in
human aortic VSMC (Figure S1). Taken together, these data demon-
strate that cAMP-signalling rapidly inhibits the basal and mitogen in-
duced levels of CCN1 mRNA and protein expression in rat and human
VSMC.
As a ﬁrst step to investigate the regulation of CCN1 in VSMC in vivo,
we studied the effect of peri-adventitial application of forskolin on
expression of CCN1 protein in rat carotid arteries after balloon injury.
CCN1 protein was undetectable in uninjured rat carotid arteries
(Fig. 3) but strongly up regulated in medial cells 7 days post-injury. Im-
portantly, forskolin treatment immediately post-injury completely
prevented injury-induced expression of CCN1 (Fig. 3).
3.3. Adenosine and Cicaprost inhibit CCN1 expression
Vasoactive agents, including adenosine and prostacyclin stimulate
cAMP production via activation of G-protein coupled receptors
(GPCRs), thus modulating VSMC function physiologically. To test
whether activation of these GPCRs inhibits CCN1 expression we stimu-
lated VSMC either with the GPCR agonists, adenosine, the speciﬁc aden-
osine A2B-receptor agonist BAY60-6583 or the prostacyclin mimetic,
Cicaprost. Adenosine and BAY60-6583 signiﬁcantly inhibited CCN1
mRNA levels after 2 and 4 h (Fig. 4A and B) and inhibited CCN1 protein
levels after 4 h (Fig. 4D and E). Cicaprost also transiently inhibited CCN1
mRNA and protein levels at 1 and 2 h, returning to control levels after
4 h (Fig. 4C and F).
3.4. Elevation of cAMP inhibits CCN1 transcription
To test whether elevated cAMP reduces CCN1 mRNA levels by
inhibiting CCN1 gene transcription we quantiﬁed CCN1 hnRNA (pre-
spliced RNA), a surrogatemeasure of transcriptional rate [41], and activ-
ity of a −2177 bp CCN1 promoter luciferase reporter (CCN1-LUC).
Forskolin treatment potently inhibited levels of CCN1 hnRNA within
1 h (to 37.5 ± 15.6% of controls; p b 0.01) with maximal inhibition
after 2 h (to 5.7 ± 4.0% of control; p b 0.001; Fig. 5A) and also inhibited
basal CCN1-LUC promoter activity after 3 and 6 h (Fig. 5B). Inhibition of
CCN1-LUC reporter activity was slower than endogenous hnRNA, pre-
sumably due to inherent differences in turnover rates of luciferase pro-
tein and CCN1 mRNA. Addition of serum mitogens to quiescent cells
signiﬁcantly stimulated CCN1-LUC activity after 2 h (2.34 ± 0.43 fold;
p N 0.05) and 6h (2.45±0.61 fold; p b 0.05); and this inductionwas sig-
niﬁcantly reduced (p b 0.05) in the presence of forskolin (Fig. 5C). Taken
together, these data indicate thatmitogens increase and cAMP elevation
inhibits CCN1 gene transcription.
3.5. Elevation of cAMP suppresses CCN1 expression via inhibition of RhoA
Elevation of cAMP is known to inhibit that activity of RhoA [22,23],
which is involved in cAMP-induced morphological changes and actin-
cytoskeleton remodelling. We therefore askedwhether RhoA and its ef-
fector, ROCK are involved in the regulation of CCN1 expression by cAMP
in VSMC. Inhibition of RhoA or ROCK activity for 6 h using C3-
transferase or Y27632, respectively, resulted in a signiﬁcant inhibition
(to 58.9 ± 13.9%, p b 0.05 for C3 transferase and to 40.3 ± 3.9%,
p b 0.05 for Y27632) of CCN1-LUC activity (Fig. 6A). C3-transferase
Fig. 3. Forskolin inhibits balloon-injury induced expression of CCN1 in rat carotid arteries in vivo. Immunohistochemical staining for CCN1 in balloon injured rat carotid arteries
treated with forskolin. Immediately after balloon injury arteries were surrounded by 200 μl of 30% pluronic gel with or without forskolin. CCN1 (green) expression was analysed by
immunohistochemistry in sections of either uninjured rat carotids or carotid arteries 7 days after balloon injury. Nuclei are stained blue with DAPI. Scale bar = 50 μm.
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and Y27632 also signiﬁcantly inhibited CCN1 mRNA levels (to 15.0 ±
2.3%, p b 0.001 for C3 transferase and to 6.7 ± 2.2%, p b 0.001 for
Y27632) after 4 h (Fig. 6B) without effecting 36B4 mRNA levels. CCN1
protein levels were similarly reduced (to 41.3 ± 4.5%, p b 0.001) by
C3 transferase and Y27632 (to 29.3 ± 13.4%, p b 0.05) after 8 h (Fig.
6C and D). We next infected cells with a recombinant adenovirus
expressing a constitutively active mutant of RhoA (Ad:RhoAG14V) to
conﬁrm a functional role for RhoA signalling. Forskolin stimulation
resulted in a 29.4 ± 7.0 fold inhibition of CCN1 mRNA expression in
control virus infected cells (Ad:Control; Fig. 6E). Infection with Ad:
RhoAG14V did not signiﬁcantly alter basal CCN1 mRNA levels. However,
forskolin stimulation only resulted in a 6.6 ± 1.18 fold inhibition of
CCN1 mRNA in cells infected Ad:RhoAG14V, representing a signiﬁcant
rescue of CCN1 expression by constitutively active RhoA.
3.6. cAMP inhibits CCN1 expression via monomeric actin
Repression of RhoA activity mediated by cAMP inhibits actin poly-
merisation [23,22], resulting in a loss of F-actin stress ﬁbres (F-actin)
and a concomitant increase in actin monomer (G-actin). We used vari-
ous actin binding drugs that inhibit or promote actin polymerisation to
test directly the role of actin polymerisation in regulation of CCN1 ex-
pression. Latrunculin-B blocks actin polymerisation, thus reducing F-
actin and increasing G-actin. Latrunculin-B treatment rapidly inhibited
(to 56.5 ± 15.9% after 30 min; p b 0.01) CCN1 mRNA, with maximal in-
hibition after 90 min (to 8.0 ± 5.4%; p b 0.001; Fig. 7A). Cytochalasin-D
inhibits actin polymerisation, thus reducing F-actin levels and increas-
ing G-actin. In contrast to latrunculin-B, cytochalasin-D also sequesters
actin monomer, effectively reducing its bio-availability to actin binding
proteins. Interestingly, cytochalasin-D treatment resulted in a transient
but signiﬁcant stimulation (5.0 ± 0.51 fold after 30 min; p b 0.001 and
3.1 ± 0.81 fold after 60 min; p b 0.05) of CCN1 mRNA levels (Fig. 7B).
Jasplakinolide,whichpromotes actin polymerisation, rapidly stimulated
(8.8 ± 2.7 fold after 30 min; p b 0.05 and 10.2 ± 3.3 fold after 60 min;
p b 0.05) CCN1 mRNA, without effecting 36B4 mRNA levels (Fig. 7C).
Taken together, these data imply that CCN1 mRNA is inhibited by ele-
vated levels of monomeric actin (G-actin), instead of being dependent
on the presence of polymerised actin. To test this hypothesis further,
we elevated monomeric actin levels in VSMC using a recombinant
adenovirus expressing a polymerisation defective mutant of actin (Ad:
ActinR62D). Infection with Ad:ActinR62D resulted in a signiﬁcant inhibi-
tion (to 35.3 ± 14%; p b 0.05) of CCN1 mRNA levels, compared to Ad:
Control infected cells, consistent with monomeric actin mediated re-
pression of CCN1 expression (Fig. 7D). We next sought to test whether
cAMP-mediated inhibition of CCN1 was dependent on monomeric
actin. For these experiments, free monomeric actin was reduced either
by polymerisation with jasplakinolide or by sequestration with
cytochalasin-D. In agreementwith our earlier data, forskolin signiﬁcant-
ly inhibited CCN1 mRNA levels (to 2.5 ± 1.1% of controls; p b 0.001) in
untreated cells. However, co-stimulation with jasplakinolide signiﬁ-
cantly (p b 0.05) attenuated the inhibitory effects of forskolin
(Fig. 7E). Likewise, co-stimulationwith cytochalasin-D also signiﬁcantly
attenuated forskolin's inhibitory effects (from 5.03 ± 2.07% of controls
for forskolin to 29.17 ± 5.7% of controls for forskolin plus
cytochalasin-D; p b 0.01; Fig. 7F). Taken together, these data indicate
that cAMP represses CCN1 expression by depolymerising actin ﬁbres
and increasing the concentration of monomeric actin. However, the
downstream mechanism linking actin monomers to CCN1 expression
remained unknown.
3.7. cAMP-dependent regulation of CCN1 via MKL and SRF
Monomeric actin has been shown in ﬁbroblasts [26] to inhibit
expression of speciﬁc subsets of SRF-dependent genes via cytoplasmic
sequestration of the SRF co-factors MKL1 and 2 [26,42]. We asked
whether cAMP regulates CCN1 expression in VSMC via this mechanism.
Fig. 4. Inhibition of CCN1 expression by Adenosine, BAY60-6582 and Cicaprost. Cells were stimulated with 100 μM adenosine; n = 3 (A, D, E), 1 μg/ml BAY-60-6583; n = 3 (B, D,
E) or 1 μMCicaprost; n= 4 (C and F) for indicated times and analysed for CCN1mRNA (A–C) and protein (D–F) expression qRT-PCR andWestern blotting. * indicates p b 0.05, ** indicates
p b 0.01, *** indicates p b 0.001. □ indicates control; indicates stimulated.
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We initially tested whether forskolin modulates, in an actin dependent
manner, SRE-dependent transcriptional activity measured with an SRE-
LUC reporter construct. Forskolin stimulation signiﬁcantly inhibited (to
32.9 ± 3.0%; p b 0.01) SRE-dependent transcriptional activity (Fig. 8A).
Inhibition of actin polymerisation with latrunculin-B also signiﬁcantly
repressed SRE activity (to 34.3 ± 11.4%; p b 0.001). Importantly, forced
actin polymerisation with jasplakinolide completely prevented
foskolin-mediated inhibition of SRE activity, consistent with actin-
dependent regulation of SRE activity by forskolin (Fig. 8A). We next
tested the role of MKL1 in forskolin inhibition of SRE-activity using a
constitutively active truncation of MKL1 (MKL1N100). This mutant
lacks the N-terminal 100 amino acids containing the actin-binding
RPEL domain and hence promotes SRE-activity in an actin-
independentmanner. Consistent with this, MKL1N100 expression signif-
icantly enhanced (by 8.9± 1.5 fold; p b 0.05) SRE-LUC activity (Fig. 8B).
More importantly, MKL1N100 completely reversed forskolin-mediated
inhibition of SRE-LUC activity (Fig. 8C), implying that cAMP regulates
SRE-activity via an MKL1-dependent mechanism. We therefore asked
whether the conserved SRE-element (at−2060 bp; Figure S2) explains
cAMP-dependent regulation of CCN1 expression. Consistent with
this possibility, expression of constitutively-active SRF (SRF-VP16)
completely prevented forskolin-mediated inhibition of CCN1 promoter
activity (Fig. 8D. Expression of wild-type MKL1 (WT-MKL1) signiﬁcant-
ly stimulated basal CCN1 promoter activity (Fig. 8E) but forskolin-
stimulation of WT-MKL1 expressing cells still signiﬁcantly inhibited
CCN1 promoter activity (Fig. 8E). Moreover, expression of active
MKL1 (MKL1N100) also signiﬁcantly stimulated CCN1 promoter activity
(Fig. 8F). However, MKL1N100 expression completely blocked forskolin-
Fig. 5. Forskolin inhibits CCN1 gene transcription. Cells were stimulated with 25 μM
Forskolin for indicated times (A, B). CCN1 pre-spliced hnRNA quantiﬁed by qRT-PCR;
n = 3 (B). Luciferase activity was quantiﬁed in cells transfected with CCN1-LUC; n = 6
(B). Quiescent cells were stimulatedwith 10% FCS for indicated in the presence or absence
of 25 μM forskolin; n = 3 (C). * indicates p b 0.05, ** indicates p b 0.01, *** indicates p b
0.001 vs. Control.□ indicates control; indicates forskolin stimulated cells.
Fig. 6. Forskolin regulates CCN1 expression via the RhoA-ROCK pathway. Cells were
stimulated with 2 μg/ml C3-transferase or 10 μM Y27632 (A–D). Luciferase activity was
quantiﬁed after 6 h in cells transfected with CCN1-LUC; n = 3 (A). CCN1 mRNA was
quantiﬁed after 4 h by qRT-PCR; n = 3 (B) and CCN1 protein after 8 h; n = 5 for C3-
transferase andn=3 for ROCK inhibitor (C) or the indicated times (D). Cellswere infected
with either Ad:Control or Ad:Rho(G14V) and stimulated with 25 μM forskolin for 2 h, 24 h
post-infection (E). CCN1mRNAwas quantiﬁed using qRT-PCR; n= 6. * indicates p b 0.05,
** indicates p b 0.01, *** indicates p b 0.001 vs. Control. □ indicates control; indicates
stimulated cells.
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mediated inhibit of CCN1 promoter activity (Fig. 8F) andmRNA expres-
sion (Fig. 8G). Most importantly, MKL1N100-dependent activation of the
CCN1 promoter (5.7± 0.81 fold; p b 0.01)was abolished bymutation of
the distal SRE-element (Fig. 8H). Furthermore, forced actin polymerisa-
tion with jasplakinolide signiﬁcantly stimulated activity (2.9 ± 0.65
fold; p b 0.01) of the wild-type but not SRE-mutated CCN1 promoter
(Figure S3), linking both actin-dependent andMKL1-dependent regula-
tion of CCN1 expression to this SRE promoter element. We next asked
whether forskolin-mediated inhibition of CCN1 expression is associated
with reduced binding of endogenousMKL1 to the CCN1 promoter using
chromatin immuno-precipitation assays (ChIP). ChIP analysis demon-
strated that serum stimulated binding of endogenous MKL1 to this
promoter region; and that binding was inhibited by co-stimulation
with forskolin or latrunculin-B (Fig. 8I). The functional signiﬁcance of
endogenous MKL1/2 for CCN1 expression was conﬁrmed using
siRNA-mediated silencing and the pharmacological MKL inhibitor,
CCG-1423. Transfection with MKL 1 and 2 siRNA signiﬁcantly sup-
pressed endogenous MKL1 and MKL2 mRNA levels 24 h post transfec-
tion (Figure S4). Serum stimulation signiﬁcantly elevated CCN1 mRNA
levels in siNEG but not siMKL1/2 transfected cells (Fig. 8J). Furthermore,
treatment with CCG-1423 signiﬁcantly inhibited CCN1 promoter activ-
ity (Fig. 8K), mRNA (Fig. 8L) and protein expression (Fig. 8M). Taken
together, these data demonstrate that mitogens increase and cAMP re-
presses SRE-dependent expression of CCN1 by inhibitingMKL1 binding
to the distal SRE-element.
4. Discussion
Increasedmigration and proliferation of VSMC aremajor factors that
contribute towards the pathological intimal thickening underlying the
development of numerous vascular pathologies, including late vein
graft failure, in-stent restenosis, pulmonary artery hypertension and
atherosclerosis. Currentmodels of disease development posit a complex
interaction of phenotypically modulated VSMCwith growth factors and
other extracellular mediators produced either in an autocrine manner
or from nearby endothelial or inﬂammatory cells. Consistent with this,
both migration and proliferation of VSMCs are triggered by combined
actions of growth factor and other (e.g. Wnt) signalling pathways, and
also depend on permissive cell–matrix and cell–cell interactions [43].
Consequently, the number of essential mediators that have been identi-
ﬁed continues to rise, despite decades of research. Our present ﬁndings
(Fig. 1) support an additional permissive role for the matri-cellular
protein CCN1 in VSMC migration and proliferation. CCN1 is a ~40 kDa
a secreted matricellular factor and member of the CCN family of
Fig. 7. Forskolin inhibits CCN1 via amonomeric actin-dependentmechanism. Cellswere treatedwith 5 μg/ml latrunculin-B (A), 2 μMcytochalasin-D (B) or 0.5 μMjasplakinolide (C) for
the indicated times; n=3. CCN1 ( ) and 36B4 (□)mRNAwere quantiﬁed using qRT-PCT (A–C). Cellswere infectedwith either Ad:Control (□) or Ad:Actin(R62D) ( ) and CCN1mRNA levels
were quantiﬁed 24 h post infection; n= 5 (D). Cells were stimulatedwith 25 μM forskolin for 90min either in the presence or absence of 0.5 μM jasplakinolide (E) or 2 μMcytochalasin-D
(F) and CCN1 mRNA levels quantiﬁed; n = 4. * indicates p b 0.05, ** indicates p b 0.01, *** indicates p b 0.001 vs. Control.
Fig. 8. Forskolin-inhibits CCN1 expression via an MKL1 and SRF-dependent mechanism. SRE-LUC activity in cells stimulated for 6 h with 5 μg/ml latrunculin B, 25 μM forskolin of
0.5 μM jasplaskinolide, as indicated; n = 3 (A). SRE-LUC activity in cells transfected with active MKL1N100 or control vector; n = 4 (B). SRE-LUC activity in control vector or MKLN100
transfected cells stimulated with 25 μM forskolin for 6 h; n = 3 (C). CCN1-LUC activity in control vector or SRF-VP16 transfected cells stimulated with 25 μM forskolin for 6 h; n = 3
(D). CCN1-LUC activity in control vector or WT-MKL transfected cells stimulated with 25 μM forskolin for 6 h; n = 3 (E). CCN1-LUC activity in control vector or MKLN100 transfected
cells stimulatedwith 25 μM forskolin for 6 h; n= 3 (F). CCN1mRNA in cells infectedwith control orMKLN100 adenoviruses stimulatedwith 25 μM forskolin for 2 h; n= 3 (G).Wild-type
and SRE-mutated CCN1-LUC activity in cells infected with control or MKLN100 adenoviruses; n = 5 (H). ChIP analysis of MKL1 binding to the distal CCN1 promoter after stimulation
with 10% FCS, 25 μM forskolin or 5 μg/ml latrunculin B for 20 min (I). CCN1 mRNA levels in cells transfected with siNEG or siMKL1/2 and stimulated with 10% FCS (black bars) for 2 h;
n = 4 (J). Effect of 18 h stimulation with 20 μM CCG1423 on CCN1-LUC activity; n = 3 (K). Effect of indicated doses of CCG1423 for 18 h on CCN1 mRNA; 1804n = 5 (L). Effect of indicated
doses of CCG1423 for 18 h on CCN1 protein levels; n=3 (M).White bars indicate unstimulated controls while black bars indicate stimulated conditions, unless otherwise indicated. * indicates
p b 0.05, ** indicates p b 0.01, *** indicates p b 0.001 vs. Control. N.S. indicates no signiﬁcant difference.
164 A. Duggirala et al. / Journal of Molecular and Cellular Cardiology 79 (2015) 157–168
immediate-response genes. On synthesis, CCN1 is secreted and
associates with the ECM or cell surface via speciﬁc integrin binding
and heparin sulphate proteoglycans tomodulate intracellular signalling
[27]. In addition, CCN1 may also directly inhibit BMP signalling or dis-
place ECM-bound bFGF, thus enhancing bFGF-induced proliferation
[29,44]. CCN1 has been previously implicated in a range cell functions,
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including cell adhesion [45], proliferation,migration [45], inﬂammation,
ECM-remodelling and gene expression [46]. CCN1 has also been impli-
cated in the development of various cardiovascular pathologies. In the
heart, CCN1 expression is elevated in patients with myocarditis, dilated
cardiomyopathy and myocardial infarction [47,48]. CCN1 is also up-
regulated in rodent models of myocardial infarction, atherosclerosis
[32], diabetic retinopathy [49], hypertension [50] andmost importantly
for this study, angioplasty restenosis [31]. In this context, lentiviral me-
diated knockdown of CCN1 was shown to suppress VSMC proliferation
and neoinitmal lesion development in vivo 14 days after balloon injury
to the rat carotid artery [31].
The focus of our present study was not to deﬁne further the produc-
tion and action of CCN1 but to investigate its down-regulation by cAMP
because interruption of the vicious cycle of VSMC migration, prolifera-
tion and disease progression has the potential limit pathological intima
formation. Consistentwith this, a large body of evidence documents the
ability of cAMP to inhibit VSMC migration and proliferation and ulti-
mately repress intima formation physiologically in vivo [6]. However,
the early cAMP-dependent signalling mechanisms underlying these
vascular protective effects are incompletely characterised and this has
probably hampered the development of clinically useful inhibitors. Ele-
vation of cAMP acts onmultiple targets to inhibit the early growth factor
and matrix-related signalling pathways. For example, decreasing levels
of Skp2 and increasing those of the cyclin-dependent kinase inhibitors
p27Kip1 and p21cip1 are of signiﬁcance for regulating the cell cycle in
VSMC [6,33]; but these are delayed effects and by no means direct tar-
gets of cAMP or the only important mechanisms. Our new data demon-
strate that decreased production of CCN1 occurs rapidly after cAMP
elevation and is an important factor regulating VSMC proliferation and
migration.
Deﬁning the precise mechanisms underlying the actions of cAMP in
VSMC could have an important impact on development of pharmaco-
logical approaches. Recent evidence from our laboratory and others
has emphasised the central role played by actin cytoskeleton remodel-
ling for many of the effects of cAMP. Elevated cAMP inhibits the activity
of members of the Rho GTPases, including RhoA and Rac1 [20,22,23],
rapidly inhibiting actin polymerisation and inducing in cultured VSMC
a ‘stellate’ morphology, characterised by a condensed cytoplasm and
loss of actin stress-ﬁbres. Precisely how these cAMP induced actin
changes modulate VSMC behaviour has remained poorly understood.
In this study, we describe a novel pathway that culminates in suppres-
sion of CCN1 transcription (Fig. 9). Our new ﬁndings elucidate each
step of this pathway by showing that cAMP elevation: (i) rapidly in-
hibits mitogen induced transcription of the CCN1 gene in vitro and vas-
cular injury induced expression of CCN1 in vivo, (ii) represses CCN1
expression by inhibiting the RhoA/ROCK pathway and disrupting actin
polymerisation, (iii) inhibits CCN1 transcription dependent on genera-
tion of monomeric actin rather than loss of actin ﬁbres, and (iv) inhibits
MKL1-dependent regulation of the distal SRE-element in the CCN1
promoter.
Taking each of these steps in turn,we ﬁrst demonstrated that elevat-
ed cAMP potently and rapidly inhibits expression of CCN1 at the level of
pre-spliced mRNA, steady-state mRNA and protein (Fig. 2). Further-
more, this occurred in response to stable cAMP analogues, adenylate cy-
clase activation with forskolin or simulation with physiological GPCR
agonists that act via cAMP, including adenosine and prostacyclin. We
showed that arterial balloon injury in vivo induces CCN1 expression
and that this is inhibited by forskolin. We previously demonstrated
that cAMP inhibits activity of several Rho GTPases [21,22]. We show
here that this mechanism is responsible for the inhibition of CCN1
gene transcription because it can bemimicked by pharmacological inhi-
bition of RhoA or ROCK and reversed by expression of a constitutively-
active RhoA mutant. These observations are consistent with previously
published studies showing, for example, that thrombin or mechanical
strain induced expression of CCN1 is dependent on RhoA activation
[51,52]. Rho GTPase activity is linked to cytoskeletal remodelling via
well characterised mechanisms and our new data demonstrate that
RhoA-mediated cytoskeletal remodelling underlies cAMP-dependent
regulation of CCN1 expression. Blocking actin polymerisation with
latrunculin-B potently inhibited CCN1 expression, whereas stimulating
actin polymerisation with jasplakinolide increased CCN1 expression. It
remained to be demonstrated whether CCN1 expression depended on
the presence of actin polymer (F-actin) or was inhibited by elevated
levels of actin monomer (G-actin). Our data strongly suggest that latter
mechanism. For example, cytochalasin-D,which inhibits actin polymer-
isation but also sequesters actin–monomer, stimulated rather than
inhibited CCN1 expression under baseline conditions. Consistently,
forced expression of a non-polymerisable actin mutant also inhibited
CCN1 expression under baseline conditions. Moreover, reducing the
availability of free actin monomer with either cytochalasin-D or
Jasplakinolide reversed the inhibitory effects of forksolin on CCN1 ex-
pression. Taken together, these results demonstrate that the cAMP-
dependent increase in monomeric actin drives inhibition of CCN1
transcription.
Increased levels of monomeric-actin, resulting from impaired actin
polymerisation, have been implicated in sequestration of the SRF co-
factor MKL1 and therefore blocking SRF-dependent regulation of
immediate-early gene expression [53]. Consistent with this, we previ-
ously demonstrated that cAMP inhibits SRF-dependent transcriptional
activity in VSMC and that forskolin inhibits nuclear translocation of
MKL1 into the nucleus [22]. For this study, we noted that the CCN1 pro-
moter contains a conserved SRE-binding element and went on to pro-
vide convincing data implicating MKL1 in cAMP-mediated inhibition
of CCN1. In detail our current data demonstrated that MKL-silencing
inhibited CCN1 expression and cAMP reduced binding of MKL1 to the
CCN1 promoter. Furthermore, the constitutively active mutant of
MKL1 (MKL1N100), lacking the N-terminal actin-binding RPEL domain,
Fig. 9. Proposedmechanismunderlying cAMP-dependent regulationofCCN1 inVSMC.
cAMP signalling rapidly inhibits the expression of CCN1 in VSMC. Elevation of cAMP
inhibits CCN1 expression via inhibition of RhoA and hence disruption of the actin
cytoskeleton. The resulting increase in monomeric actin leads to inhibition of MKL1-
dependent SRF transcriptional activity and reduces CCN1. Reduced expression of CCN1
contributes towards inhibition of proliferation and migration.
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completely prevented forskolin-mediated reduction in CCN1 expres-
sion. Furthermore, we showed by mutation analysis that the ability of
MKL1 and actin polymerisation to regulate CCN1 expression is absolute-
ly dependent on the distal SRE promoter element. The implication of
these data is that cAMP-mediated inhibition of RhoA and the subse-
quent reduction in actin polymerisation leads to reduced MKL1-SRF-
dependent CCN1 expression (Fig. 9). Consistent with this, forced actin
polymerisation with Jasplakinolide or actin monomer sequestration
with cytochalasin-D blocks the effects of forskolin on SRE transcription-
al activity or CCN1 promoter activity.
4.1. Conclusions
In summary, this study demonstrates that CCN1 stimulates VSMC
proliferation, migration and chemotaxis. Moreover, it shows for the
ﬁrst time that cAMP signalling rapidly inhibits the expression of CCN1
in VSMC in vitro and in vivo. Elevation of cAMP inhibits CCN1 expression
via inhibition of RhoA and hence disruption of the actin cytoskeleton.
The resulting increase in monomeric actin leads to inhibition of MKL1-
dependent SRF transcriptional activity and reduces CCN1 transcription.
This represents a novel cAMP-sensitive signalling pathway (Fig. 9) that
controls the expression of CCN1 and very likely other SRE-dependent
immediate response genes also. Our study highlights the previously un-
derappreciated importance of actin-cytoskeleton remodelling in medi-
ating the biological effects of cAMP in VSMC and suggests several new
targets for pharmacological intervention
Disclosures
None
Acknowledgements
This work was supported by British Heart Foundation [Grant num-
ber PG/11/78/29113] and by the NIHR Bristol BRU in Cardiovascular
Medicine. We thank Gill Tarlton and Sue Finerty for their expert
support.
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.yjmcc.2014.11.012.
References
[1] Newby AC, Southgate KM. Serum-induced proliferation of rabbit aortic smoothmus-
cle cells from the contractile state is inhibited by 8-Br-cAMP but not 8-Br-cGMP.
Atherosclerosis 1990;82:113–23.
[2] Orlov SN, Thorin-Trescases N, Dulin NO, Dam TV, Fortuno MA, Tremblay J, et al. Ac-
tivation of cAMP signaling transiently inhibits apoptosis in vascular smooth muscle
cells in a site upstream of caspase-3. Cell Death Differ 1999;6:661–72.
[3] Chen WJ, Chen YH, Lin KH, Ting CH, Yeh YH. Cilostazol promotes vascular smooth
muscles cell differentiation through the cAMP response element-binding protein-
dependent pathway. Arterioscler Thromb Vasc Biol 2011;31:2106–13.
[4] Roberts OL, Kamishima T, Barrett-Jolley R, Quayle JM, Dart C. Exchange protein acti-
vated by cAMP (Epac) induces vascular relaxation by activating Ca2 + -sensitive K
+ channels in rat mesenteric artery. J Physiol-Lond 2013;591:5107–23.
[5] Parnell E, Smith BO, Palmer TM, Terrin A, Zaccolo M, Yarwood SJ. Regulation of the
inﬂammatory response of vascular endothelial cells by EPAC1. Br J Pharmacol
2012;166:434–46.
[6] Wu Y, Bond M, Sala-Newby G, Newby A. Altered S-phase kinase-associated protein-
2 levels are a major mediator of cyclic nucleotide-induced inhibition of vascular
smooth muscle cell proliferation. Circ Res 2006;98:1141–50.
[7] Palmer D, Maurice DH. cAMP-mediated inhibition of vascular smooth muscle cell
migration: role of cAMP-phosphodiesterases. Mol Biol Cell 1997;8:764.
[8] Howe A. Regulation of actin-based cell migration by cAMP/PKA. Biochim Biophys
Acta Mol Cell Res 2004;1692:159–74.
[9] Indolﬁ C, Di Lorenzo E, Rapacciuolo A, Stingone AM, Stabile E, Leccia A, et al. 8-
chloro-cAMP inhibits smoothmuscle cell proliferation in vitro and neointima forma-
tion induced by balloon injury in vivo. J Am Coll Cardiol 2000;36:288–93.
[10] Savai R, Pullamsetti SS, Banat GA, Weissmann N, Ghofrani HA, Grimminger F, et al.
Targeting cancer with phosphodiesterase inhibitors. Expert Opin Investig Drugs
2010;19:117–31.
[11] Netherton SJ, Jimmo SL, Palmer D, Tilley DG, Dunkerley HA, Raymond DR, et al.
Altered phosphodiesterase 3-mediated cAMP hydrolysis contributes to a
hypermotile phenotype in obese JCR : LA-cp rat aortic vascular smooth muscle
cells - Implications for diabetes-associated cardiovascular disease. Diabetes
2002;51:1194–200.
[12] Jeremy JY, Dashwood MR, Timm M, Izzat MB, Mehta D, Bryan AJ, et al. Nitric oxide
synthase and adenylyl and guanylyl cyclase activity in porcine interposition vein
grafts. Ann Thorac Surg 1997;63:470–6.
[13] Jeremy JY, Birkett SD, Bryan AJ, Angelini GD. The inﬂuence of surgical preparation on
cyclic nucleotide synthesis in an organ culture of human saphenous vein. Eur J Vasc
Endovasc Surg 1997;13:72–8.
[14] Jeremy JY, Dashwood MR, Mehta D, Izzat MB, Shukla N, Angelini GD. Nitric oxide,
prostacyclin and cyclic nucleotide formation in externally stented porcine vein
grafts. Atherosclerosis 1998;141:297–305.
[15] Yokoyama U, Minamisawa S, Quan H, Akaike T, Jin MH, Otsu K, et al. Epac1 is upreg-
ulated during neointima formation and promotes vascular smooth muscle cell mi-
gration. Am J Physiol Heart Circ Physiol 2008;295:H1547–55.
[16] Schauer IE, Knaub LA, Lloyd M, Watson PA, Gliwa C, Lewis KE, et al. CREB downreg-
ulation in vascular disease a common response to cardiovascular risk. Arterioscler
Thromb Vasc Biol 2010;30:733–41.
[17] Murray F, Patel HH, Suda RYS, Zhang S, Thistlethwaite PA, Yuan JXJ, et al. Expression
and activity of cAMP phosphodiesterase isoforms in pulmonary artery smooth mus-
cle cells from patients with pulmonary hypertension: role for PDE1. Am J Physiol
Lung Cell Mol Physiol 2007;292:L294–303.
[18] Jing Q, Xin SM, Cheng ZJ, Zhang WB, Zhang R, Qin YW, et al. Activation of
p38 mitogen-activated protein kinase by oxidized LDL in vascular smooth muscle
cells - Mediation via pertussis toxin-sensitive G proteins and association with oxi-
dized LDL-induced cytotoxicity. Circ Res 1999;84:831–9.
[19] Mayr B, MontminyM. Transcriptional regulation by the phosphorylation-dependent
factor CREB. Nat Rev Mol Cell Biol 2001;2:599–609.
[20] Bond M, Wu YJ, Sala-Newby GB, Newby AC. Rho GTPase, Rac(1), regulates
Skp(2) levels, vascular smooth muscle cell proliferation, and intima formation
in vitro and in vivo. Cardiovasc Res 2008;80:290–8.
[21] Hewer RC, Sala-Newby GB, Wu YJ, Newby AC, Bond M. PKA and Epac synergistically
inhibit smooth muscle cell proliferation. J Mol Cell Cardiol 2011;50:87–98.
[22] Kimura TE, Duggirala A, Hindmarch CCT, Hewer RC, Cui MZ, Newby AC, et al. Protein
kinase A and EPAC synergistically inhibit Egr1 expression and proliferation in vascu-
lar smooth muscle cells. JMCC 2014;72:9–19.
[23] Pelletier S, Julien C, Popoff M, Lamarche-Vane N, Meloche S. Cyclic AMP induces
morphological changes of vascular smooth muscle cells by inhibiting a Rac-
dependent signaling pathway. J Cell Physiol 2005;204:412–22.
[24] Assoian RK, Schwartz MA. Coordinate signaling by integrins and receptor tyrosine
kinases in the regulation of G1 phase cell-cycle progression. Curr Opin Genet Dev
2001;11:48–53.
[25] Aplin AE, Stewart SA, Assoian RK, Juliano RL. Integrin-mediated adhesion regulates
ERK nuclear translocation and phosphorylation of Elk-1. J Cell Biol 2001;153:
273–81.
[26] Miralles F, Posern G, Zaromytidou AI, Treisman R. Actin dynamics control SRF activ-
ity by regulation of its coactivator MAL. Cell 2003;113:329–42.
[27] Emre Y, Imhof BA. Matricellular protein CCN1/CYR61: a new player in inﬂammation
and leukocyte trafﬁcking. Semin Immunopathol 2014;36:253–9.
[28] Chaqour B, Goppelt-Struebe M. Mechanical regulation of the Cyr61/CCN1 and CTGF/
CCN2 proteins - Implications in mechanical stress-associated pathologies. FEBS J
2006;273:3639–49.
[29] Lau LF. CCN1/CYR61: the very model of a modernmatricellular protein. Cell Mol Life
Sci 2011;68:3149–63.
[30] Mo FE, Muntean AG, Chen CC, Stolz DB, Watkins SC, Lau LF. CYR61 (CCN1) is essen-
tial for placental development and vascular integrity. Mol Cell Biol 2002;22:
8709–20.
[31] Matsumae H, Yoshida Y, Ono K, Togi K, Inoue K, Furukawa Y, et al. CCN1 knockdown
suppresses neointimal hyperplasia in a rat artery balloon injury model. Arterioscler
Thromb Vasc Biol 2008;28:1077–83.
[32] Hilﬁker A, Hilﬁker-Kleiner D, Fuchs M, Kaminski K, Lichtenberg A, Rothkotter HJ,
et al. Expression of CYR61, an angiogenic immediate early gene, in arteriosclerosis
and its regulation by angiotensin II. Circulation 2002;106:254–60.
[33] Bond M, Sala-Newby G, Wu Y, Newby A. Biphasic effect of p21Cip1 on vascular
smooth muscle cell proliferation: role of PI3-kinase signalling and Skp2-mediated
degradation. Cardiovasc Res 2006;69:198–206.
[34] Wu Y-J, Sala-Newby GB, Shu K-T, Yeh H-I, Nakayama KI, Nakayama K, et al. S-phase
kinase-associated protein-2 (Skp2) promotes vascular smooth muscle cell prolifera-
tion and neointima formation in vivo. J Vasc Surg 2009;50:1135–42.
[35] Muehlich S, Wang R, Lee S-M, Lewis TC, Dai C, Prywes R. Serum-induced phosphor-
ylation of the serum response factor coactivator MKL1 by the extracellular signal-
regulated kinase 1/2 pathway inhibits its nuclear localization. Mol Cell Biol 2008;
28:6302–13.
[36] Schratt G, Philippar U, Berger J, Schwarz H, Heidenreich O, Nordheim A. Serum re-
sponse factor is crucial for actin cytoskeletal organization and focal adhesion assem-
bly in embryonic stem cells. J Cell Biol 2002;156:737–50.
[37] Hernandez-Negrete I, Sala-Newby GB, Perl A, Kunkel GR, Newby AC, Bond M.
Adhesion-dependent Skp2 transcription requires selenocysteine tRNA gene
transcription-activating factor (STAF). Biochem J 2011;436:133–43.
[38] Burdyga A, Conant A, Haynes L, Zhang J, Jalink K, Sutton R, et al. cAMP inhibits migra-
tion, rufﬂing and paxillin accumulation in focal adhesions of pancreatic ductal
167A. Duggirala et al. / Journal of Molecular and Cellular Cardiology 79 (2015) 157–168
adenocarcinoma cells: effects of PKA and EPAC. Biochim Biophys Acta Mol Cell Res
1833;2013:2664–72.
[39] Liu L, Xu X, Li J, Li X, Sheng W. Lentiviral-mediated shRNA silencing of PDE4D gene
inhibits platelet-derived growth factor-induced proliferation and migration of rat
aortic smooth muscle cells. Stroke Res Treat 2011:534257.
[40] Koyama N, Morisaki N, Saito Y, Yoshida S. Regulatory effects of platelet-derived
forwth factor-AA homodimer on migration of vascular smooth muscle cells. J Biol
Chem 1992;267:22806–12.
[41] Elferink CJ, Reiners JJ. Quantitative RT-PCR on CYP1A1 heterogeneous nuclear RNA: a
surrogate for the in vitro transcription run-on assay. Biotechniques 1996;20:470–7.
[42] Posern G, Miralles F, Guettler S, Treisman R. Mutant actins that stabilise F-actin use
distinct mechanisms to activate the SRF coactivator MAL. Embo J 2004;23:3973–83.
[43] BondM,Wu Y-J. Proliferation unleashed: the role of Skp2 in vascular smooth muscle
cell proliferation. Front Biosci Landmark 2011;16:1517–35.
[44] Kolesnikova TV, Lau LF. Human CYR61-mediated enhancement of bFGF-induced DNA
synthesis in human umbilical vein endothelial cells. Oncogene 1998;16:747–54.
[45] Grote K, Salguero G, Ballmaier M, Dangers M, Drexler H, Schieffer B. The angiogenic
factor CCN1 promotes adhesion and migration of circulating CD34(+) progenitor
cells: potential role in angiogenesis and endothelial regeneration. Blood 2007;110:
877–85.
[46] Qin ZP, Fisher GJ, Quan TH. Cysteine-rich protein 61 (CCN1) domain-speciﬁc stimu-
lation of matrix metalloproteinase-1 expression through alpha V beta 3 integrin in
human skin ﬁbroblasts. J Biol Chem 2013;288:12386–94.
[47] Hilﬁker-Kleiner D, Kaminski K, Kaminska A, Fuchs M, Klein G, Podewski E, et al. Reg-
ulation of proangiogenic factor CCN1 in cardiac muscle - Impact of ischemia, pres-
sure overload, and neurohumoral activation. Circulation 2004;109:2227–33.
[48] Wittchen F, Suckau L, Witt H, Skurk C, Lassner D, Fechner H, et al. Genomic expres-
sion proﬁling of human inﬂammatory cardiomyopathy (DCMi) suggests novel ther-
apeutic targets. J Mol Med 2007;85:253–67.
[49] Hughes JM, Kuiper EJ, Klaassen I, Canning P, Stitt AW, Van Bezu J, et al. Advanced
glycation end products cause increased CCN family and extracellular matrix gene
expression in the diabetic rodent retina. Diabetologia 2007;50:1089–98.
[50] Unoki H, Furukawa K, Yonekura H, Ueda Y, Katsuda S, Mori M, et al. Up-regulation of
cyr61 in vascular smoothmuscle cells of spontaneously hypertensive rats. Lab Invest
2003;83:973–82.
[51] Walsh CT, Radeff-Huang J, Matteo R, Hsiao A, Subramaniam S, Stupack D, et al.
Thrombin receptor and RhoA mediate cell proliferation through integrins and
cysteine-rich protein 61. FASEB J 2008;22:4011–21.
[52] Hanna M, Liu HB, Amir J, Sun Y, Morris SW, Siddiqui MAQ, et al. Mechanical regula-
tion of the proangiogenic factor CCN1/CYR61 gene requires the combined activities
of MRTF-A and CREB-binding protein histone acetyltransferase. J Biol Chem 2009;
284:23125–36.
[53] Sotiropoulos A, Gineitis D, Copeland J, Treisman R. Signal-regulated activation of
serum response factor is mediated by changes in actin dynamics. Cell 1999;98:
159–69.
Glossary
BrdU: 5-Bromo-2-deoxyuridine
cAMP: 3′-5′-Cyclic adenosine monophosphate
CREB: cAMP response element binding protein
SRE: Serum response element
SRF: Serum response factor
VSMC: Vascular smooth muscle cell
RhoA: Ras homolog family member A
Rac: Ras-related C3 botulinum toxin substrate 1
VSMC: Vascular smooth muscle cell
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